Supplementary Information:-

A novel Monoclonal Antibody against Notch1 Targets Leukemiaassociated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors

Ankur Sharma¹, Rupali A Gadkari², Satthenapalli V Ramakanth^{1\$}, Krishnanand Padmanabhan^{1\$}, Davanam S Madhumathi³, Lakshmi Devi³, Lingappa Appaji⁴, Jon C Aster⁵, Annapoorni Rangarajan¹ and Rajan R Dighe¹#

¹Department of Molecular Reproduction Development and Genetics, Indian Institute of Science Bangalore, Karnataka, India ²Molecular Biophysics Unit, Indian Institute of Science Bangalore, Karnataka, India ³Department of Pathology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India ⁴Department of Pediatric Oncology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India ⁵Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, USA \$- SVR and KP equally contributed to the work.

*Running Title: Targeting Notch1 Signaling in Cancer Stem Cells

*Corresponding author:

Rajan R Dighe, Professor, Department of Molecular Reproduction Development and Genetics, Indian Institute of Science, Bangalore 560012, India, Tel: 9180-2293-2660/3261

Fax: 9180-2360-0999, Email: rdighe@mrdg.iisc.ernet.in

Supplementary Legends:

Supplementary Figure 1: Notch1 mutational analysis in T-ALL patients.

Supplementary Figure 2: (A) Effect of MAb 604.107 on LIC subpopulation: The CD34^{High}/CD45^{High} cells were flow-sorted from the patient derived PBL's followed by culture with control IgG or the MAb 604.107 (10µg/ml) for 72 hours and BrdU incorporation into DNA was determined. (B) Effect of MAb 604.107 on Notch target genes in CCRF-CEM cells.

Supplementary Figure 3: Effect of MAb604.107 on long-term self-renewing sphere forming cells. Breast cancer cell lines MCF-7 and MDA-MB-231 cells were allowed to form sphere in semisolid medium in presence of MAb 604.107 for 1 week followed by second generation of sphere formation in the absence of MAb.

Supplementary Figure 4: Effect of MAb 604.107 on NICD-1, Hes-1, Caspase-3 and BCI-2 expression. MDA-MB-231 and HCT-116 cells were treated with control of MAb604.107 (20µg/ml) for 48 hours at the end of which whole cell lysate was prepared and level of NICD-1, Hes-1, Caspase-3 and BCI-2 was evaluated in western blot. Beta-actin was used as normalizing control.

Supplementary Figure 5: Effect of anti-Notch1 antibody treatment on stemness genes in breast and colon cancer cell lines.

Supplementary Figure 6: Effect of anti-Notch1 antibody treatment on EMT genes in breast and colon cancer cell lines.

Supplementary Figure 7: Effect of MAb604.107 on Dox resistant cell lines. MDA-MB-231 and HCT-116 cells were cultured in the presence of Dox for three week and Dox-resistant cells lines were established. (A) Expression level of NICD-1 in Dox sensitive and resistant cells. (B) Dox sensitive and resistant MDA-MB-231 and HCT-116 cells were cultured in the presence of control IgG or MAb (20µg/ml) and BrdU incorporation was determined.

Supplementary Figure 8: Effect of anti-Notch1 antibody treatment on Notch downstream targets and stemness genes in xenografts.

Supplementary Figure 9: Expression of NICD-1 in control of MAb treated (A) MDA-MB-231 and (B) HCT-116 xenografts.

Supplementary Figure 10: ELISA based epitope mapping of MAb604.107

Supplementary Table 1: Phage-display screening for epitope mapping.

Supplementary Table 2: Comparison between MAb604.107 with previously reported inhibitory ant-Notch1 Mab.











M D A - M B - 231





M D A - M B - 231



M D A - M B - 231



Control IgG

MAb 604.107

Т

1 0^{ct^{-A}}





Hanos

1 50¹





Fold Change

5.

4

3•

2 -

1 -

0.







MDA-MB-231

Control IgG treated tumors

604.107 treated tumors



HCT-116



Supplementary Table-1

MAb	Putative epitopes in Notch1 NRR domain	NRR domain
604.107	LRNSSFHFLRELSRVL HTNVVFKRD	Heterodimerization (HD) domain
604.107	SLNFNDPWKNCTQSL QCWKYFS	LNR-A
604.132	IFPYYGREEELRK	HD
604.132	SLNFNDPWKNCTQSL QCWKYFS	LNR-B
604.164	HGQQMIFPYY	HD

Supplementary Table-2

Properties of MAb	Present study 604.107 (Sharma et al.,)	Previous study ¹⁸ (Wu et al., Nature 2010)
Effect on wild-type Notch signaling	Inhibitory (at higher dose)	Inhibitory
Affinity for wild-type Notch1	5.08x10 ⁻⁸	2.5x10 ⁻⁹
Effect on mutant Notch1	Inhibitory (both at higher and lower doses)	Inhibitory
Affinity for mutant Notch1	5.08x10 ⁻⁹	ND
Specificity for mutant Notch1	At lower concentration specific for mutant Notch1 without affecting wild-type signaling	ND
Effect on LIC subpopulation	Deplete LIC subpopulation	ND
Impact on CSC and chemoresistance cells	Irreversibly inhibit CSCs	ND

ND- not determined